GRAIL Faces Securities Class Action Over Alleged Misleading Disclosures in Failed NHS-Galleri Trial
GRAL has more than doubled off its 52-week low of $29.95 on light trading volume (0.4× avg).
Summary
Hagens Berman has announced a securities class action lawsuit against GRAIL, Inc., alleging the company misled investors regarding its NHS-Galleri trial. The lawsuit claims GRAIL made false statements about the trial's design and its likelihood of achieving its primary endpoint, which it failed to do on February 19, 2026. This failure resulted in a $2.2 billion market capitalization decline. While GRAIL reported strong Q1 2026 financial results in May, this class action introduces significant legal and financial risk, questioning management's prior disclosures. The lead plaintiff deadline for the lawsuit is August 4, 2026.
At the time of this announcement, GRAL was trading at $68.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $29.95 to $118.84. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.